Stockreport

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally [Yahoo! Finance]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF On February 17, 2026, Vestal Point Capital disclosed in a Securities and Exchange Commission (SEC) filing that it sold 1,054,000 shares of Nuvalent (NASDAQ:NUVL) , an e [Read more]